What is Swoop?
Swoop operates at the intersection of artificial intelligence and patient-centric healthcare marketing. By leveraging a massive data universe comprising over 300 million de-identified patients and 65 billion anonymous consumer interactions, the company provides pharmaceutical brands with the tools to educate patients on disease states and treatment options. The platform is HIPAA-certified and NAI-accredited, ensuring that its cross-channel marketing strategies are both compliant and highly effective. By utilizing machine learning to identify unique target audiences, Swoop enables healthcare ecosystems to drive optimal conversion rates and increase prescription lift, effectively transforming how patients participate in their own treatment journeys.
How much funding has Swoop raised?
Swoop has raised a total of $13.4M across 4 funding rounds:
Series A
$4.8M
Other Financing Round
$3M
Series B
$3.5M
Debt
$2.1M
Series A (2011): $4.8M with participation from U.S. Venture Partners, Valhalla Partners, and General Catalyst Partners
Other Financing Round (2012): $3M led by U.S. Venture Partners and Valhalla Partners
Series B (2013): $3.5M supported by U.S. Venture Partners
Debt (2014): $2.1M featuring U.S. Venture Partners
Key Investors in Swoop
U.S. Venture Partners
U.S. Venture Partners is a prominent Silicon Valley venture capital firm dedicated to collaborating with entrepreneurs to develop transformative companies, with a specific focus on healthcare and enterprise software.
General Catalyst Partners
General Catalyst is a venture capital firm that identifies and supports transformational business opportunities, leveraging deep operational experience to help companies scale at critical inflection points.
Valhalla Partners
Valhalla Partners is a venture capital firm focused on building enduring technology companies by providing seasoned advice and best practices developed over two decades of industry experience.
What's next for Swoop?
Following this major strategic investment, Swoop is well-positioned to scale its operations and further refine its predictive modeling capabilities. The company's trajectory suggests a focus on expanding its real-world evidence data sets and deepening its integration within the pharmaceutical marketing landscape. As the demand for precision medicine and personalized patient engagement continues to rise, Swoop's ability to leverage social determinants of health and outcomes research will likely serve as a primary competitive advantage. Future growth will likely center on enhancing the platform's AI-driven insights to maintain its status as an essential partner for global pharmaceutical enterprises seeking to improve patient outcomes through data-backed communication strategies.
See full Swoop company page
